



Published on The Well Project (<https://www.thewellproject.org>)  
<https://www.thewellproject.org/hiv-information/wri-2011-antiretroviral-arv-use-women-prevention-and-treatment-hiv-disease>

## **WRI 2011 - Antiretroviral (ARV) Use in Women for the Prevention and Treatment of HIV Disease**

Submitted on May 2, 2011

Image



**WOMEN'S  
RESEARCH  
INITIATIVE  
ON HIV/AIDS**

The 2011 meeting of the WRI focused on the issues surrounding antiretroviral (ARV) use in women for the prevention and treatment of HIV disease. This theme was selected in order to encompass the broad range of interdisciplinary work that is both ongoing and necessary to effectively prevent and manage HIV disease in women. Although the development of an impressive range of effective ARV drugs has created the possibility of a chronic disease state, the realities of access, uptake, manageability, acceptability and long-term effectiveness prevent us from achieving this desired outcome. This makes it

incumbent upon all stakeholders to take a more comprehensive approach to HIV research, including among women.



The 2011 Annual WRI Meeting took place from March 17-20 in Adairsville, GA with 22 members of the WRI participating (including representatives from clinical care, HIV research, academia, community-based organizations, government, the pharmaceutical industry and HIV-positive women), as well as guest speakers and invited experts. A list of the 2011 WRI Meeting members, speakers and participants can be found below.

Click the link below to view the Full Summary Report from the 2011 WRI Annual Meeting. We've also included links to brief interviews/testimonials from a few WRI participants about their experiences at the meeting and photos from the meeting.

- [2011 WRI Full Summary Report \(1 MB\)](#)
- [WRI Participant Perspective: Read what some participants had to say about the 2011 meeting and their experiences](#)
- Photos from 2011 WRI Meeting: [Day 1](#) and [Day 2](#)

## **WRI 2011 Meeting Approach and Speaker Presentations**

To highlight the most critical research efforts and findings of the past year, invited expert speakers and WRI members presented their work on key topics in biologic, behavioral and social research in women and HIV. Each of these talks fueled rich discussion and often culminated in unique synthesis and perspective by the group.

Invited speakers and topics included:



- [PrEP and Microbicides](#); Sharon Hillier, PhD, University of Pittsburgh Department of OB/Gyn/RS and Microbiology and Molecular Genetics. Reviewed recent and ongoing research into biomedical prevention with a focus on women; addressed implications for pregnancy; described the difference between options and choice for HIV prevention tools among women

- [Biologic Correlates of Risk and Aging](#); Amie L. Meditz, MD, Division of Infectious Diseases, University of Colorado Denver. Evaluated the role of CCR5 and CD4 T-cells in HIV acquisition among post-menopausal women
- [Contextualizing the WRI: Key Science and Policy Issues](#); Judith Auerbach, PhD, San Francisco AIDS Foundation. Described key current relevant science and policy factors, including recent biomedical prevention advances, National HIV/AIDS Strategy, Patient Protection and Affordable Care Act of 2010, federal HIV research funding
- [Overview of Cohorts of HIV-infected Women and Girls](#); Monica Gandhi MD, MPH, Divisions of HIV/AIDS and Infectious Diseases; HIV Consult Service, University of California, San Francisco; presented by Gina Brown, MD, Office of AIDS Research, NIH. Described data generated by NIH cohorts, NIH-funded clinical trial cohorts and other cohorts from around the world

## 2011 WRI Meeting Participants

**Erika Aaron, MSN, CRNP (WRI attendee)**

Drexel University College of Medicine **Kathryn Anastos, MD (WRI member)**

Montefiore Medical Center **Laura Armas-Kolostroubis, MD\* (WRI member)**

Texas/Oklahoma AIDS Education and Training Center **Judith Auerbach, PhD\* (WRI member and speaker)**

San Francisco AIDS Foundation **Richard Averitt (WRI team)**

The Well Project **Julie Barroso, PhD, ANP, APRN, BC, FAAN (WRI member)**

Duke University School of Nursing **Dawn Averitt Bridge\* (WRI member)**

The Well Project **Gina Brown, MD\* (WRI member and speaker)**

Office of AIDS Research, NIH **Susan E. Cohn, MD, MPH (WRI member)**

Northwestern University Feinberg School of Medicine **Elizabeth Connick, MD (WRI member)**

University of Colorado Denver **Jenna Conley (WRI team)**

Conley Communications **Debbie Cooke, CMP (WRI team)**

Meeting Masters **Rebecca Denison (WRI member)**

WORLD **Dazon Dixon Diallo (WRI attendee)**

SisterLove, Inc. **Shari Dworkin, PhD, MS (WRI member)**

University of California, San Francisco **Shalini Eddens, MPH (WRI team)**

The Well Project **Judith Feinberg, MD\* (WRI member)**

University of Cincinnati **Carrie Elizabeth Foote, PhD (WRI member)**

Indiana University-Indianapolis **Yasmin Halima, MPH (WRI member)**

Global Campaign for Microbicides **Sharon Hillier, PhD (WRI member and speaker)**

University of Pittsburg Medical Center **Rowena Johnston, PhD (WRI member)**

amfAR - The Foundation for AIDS Research **Alan Landay, PhD (WRI member)**

Rush University Medical Center **Sharon Lee, MD (WRI member)**

Family Health Care **Sandra N. Lehrman (WRI attendee)**

Merck and Co., Inc. **Krista Heitzman Martel (WRI team)**

The Well Project **Louise Martin-Carpenter (WRI attendee)**

ViiV Healthcare **Henry L. Masters III, MD (WRI attendee)**

Boehringer Ingelheim **Amie Lynne Meditz, MD (WRI attendee and speaker)**

University of Colorado Denver **Caroline Mitchell, MD, MPH (WRI member)**

University of Washington

Harborview OB/GYN **Tonia Poteat, PA-C, MPH (WRI member)**

Chase Brexton Health Services **Kim Reed (TWP Board Member, WRI attendee)**

Reed International Law and Consulting, LLC **Maura Riordan (TWP Board Member, WRI attendee)**

AIDS United **Monica Ruiz, PhD, MPH (WRI member)**

George Washington University **Valerie Scott (TWP Board Member, WRI attendee)**

The Strategic Continuum Company **Kathleen Squires, MD (WRI member)**

Thomas Jefferson University **Stephen P. Storfer, MD\* (WRI member)**

WRI Executive Committee **Kimberly Struble, PharmD (WRI member)**

Food and Drug Administration (FDA) **Jonathan Uy, MD (WRI attendee)**

Bristol-Myers Squibb **Fulvia Veronese, PhD (WRI attendee)**

NIH, NIAID, DAIDS **Kirsten White, PhD (WRI attendee)**

Gilead Sciences, Inc. **Charles Wira, PhD (WRI member)**

Dartmouth Medical School

*\* 2011 WRI Executive Committee member*



@ 2023 thewellproject. All rights reserved.